LEADER 03137nam  2200625Ia 450 
001 9910817223903321
005 20240417003502.0
010   $a0-309-18061-9
010   $a1-280-70492-6
010   $a9786610704927
010   $a0-309-65814-4
035   $a(CKB)1000000000469281
035   $a(OCoLC)560385115
035   $a(CaPaEBR)ebrary10150106
035   $a(SSID)ssj0000137700
035   $a(PQKBManifestationID)11130061
035   $a(PQKBTitleCode)TC0000137700
035   $a(PQKBWorkID)10088698
035   $a(PQKB)11501473
035   $a(MiAaPQ)EBC3378153
035   $a(Au-PeEL)EBL3378153
035   $a(CaPaEBR)ebr10150106
035   $a(CaONFJC)MIL70492
035   $a(OCoLC)923277128
035   $a(EXLCZ)991000000000469281
100   $a20060807d2006      uy         0
101 0 $aeng
135   $aurcn|||||||||
181   $ctxt
182   $cc
183   $acr
200 10$aDeveloping biomarker-based tools for cancer screening, diagnosis, and treatment$b[electronic resource] $ethe state of the science, evaluation, implementation, and economics /$fMargie Patlak and Sharyl Nass, rapporteurs ; National Cancer Policy Forum
205   $a1st ed.
210   $aWashington, DC $cNational Academies Press$dc2006
215   $a1 online resource (112 p.) 
300   $aBibliographic Level Mode of Issuance: Monograph
311   $a0-309-10134-4 
320   $aIncludes bibliographical references.
327   $aFrontmatter -- Reviewers -- Contents -- Introduction -- Overview of Technologies Used to Discover Cancer Biomarkers -- Meeting the Technical Challenges of Biomarker Validation and Qualification -- Coordinating the Development of Biomarkers and Targeted Therapies -- Biomarker Development and Regulatory Oversight -- Assessment and Adoption of Biomarker-Based Technologies -- Economic Impact of Biomarkers -- Clinical Development Strategies for Biomarker Utilization Discussion -- Strategies for Implementing Standardized Biorepositories Discussion -- Strategies for Determining Analytic Validity and Clinical Utility of Biomarkers Discussion -- Strategies to Develop Biomarkers for Early Detection Discussion -- Mechanisms for Developing an Evidence Base Discussion -- Evaluation of Evidence in Decision Making Discussion -- Incorporating Biomarker Evidence Into Clinical Practice Discussion -- Acronyms -- Glossary -- References -- Appendixes -- Appendix A Workshop Agenda -- Appendix B Workshop Speakers, Moderators, Invited Discussants, and Participants.
606   $aTumor markers$vCongresses
606   $aBiochemical markers$vCongresses
615  0$aTumor markers
615  0$aBiochemical markers
676   $a616.99/4075
700   $aPatlak$b Margie$01607028
701   $aNass$b Sharyl J$0857626
712 02$aNational Cancer Policy Forum (U.S.)
712 02$aUnited States.$bDept. of Health and Human Services.
801  0$bMiAaPQ
801  1$bMiAaPQ
801  2$bMiAaPQ
906   $aBOOK
912   $a9910817223903321
996   $aDeveloping biomarker-based tools for cancer screening, diagnosis, and treatment$93981885
997   $aUNINA